[Breast Cancer: Targets and Therapy] A review of the potential of immunotherapy along and in combination with standard therapies for breast cancer, in particularly HER2-positive expressing subtypes.
Results of a retrospective chart review of patients with BRAF-mutant metastatic melanoma receiving sequential treatment with immunotherapy and targeted therapy or vice versa are presented.
Three experts describe their predictions for what lies ahead in 2019 regarding immunotherapy, research, and disparities in cancer care.